ACY-1215 is an inhibitor of histone deacetylase 6 (HDAC6; IC
50 = 5 nM).
1 It is at least 10-fold less active against other HDACs in enzymatic assays. ACY-1215 shows synergistic activity with the proteasome inhibitor bortezomib (Item No.
10008822) against multiple myeloma (MM) cells, inducing protracted endoplasmic reticulum stress and apoptosis.
1,2 ACY-1215 combined with proteasome inhibitors suppresses tumor growth and increases survival in mice with MM and mantle cell lymphoma xenografts.
2,1,3 A multicenter phase I trial examining ACY-1215 combined with the E3 ligase inhibitor lenalidomide (Item No.
14643) and dexamethasone (Item No.
11015) in multiple myeloma found inhibition of HDAC6
in vivo.
4 ACY-1215 also diminishes liver cyst development and fibrosis in a rat model of polycystic liver disease.
5 
